NEW YORK, NY / ACCESSWIRE / September 26, 2018 / U.S. equities were mixed on Tuesday as concerns of a potential trade war linger and investors look forward to details from the upcoming Fed monetary policy meeting. The Dow Jones Industrial Average dropped 0.26 percent to close at 26,492.21, while the S&P 500 Index declined 0.13 percent to close at 2,915.56. The Nasdaq Composite Index rose 0.18 percent to close at 8,007.47.
“Investors have been digesting the idea of a full-blown trade war for months now, and on top of that, they are already aware of what could be the next steps. Yesterday’s market reaction corroborates our view,” said Charalambos Pissouros, senior market analyst at JFD Brokers.
RDI Initiates Coverage on:
Jaguar Health, Inc.
TG Therapeutics, Inc.
Jaguar Health's stock jumped 158.46% Tuesday, to close the day at $1.68. The stock recorded a trading volume of 47,387,097 shares, which was above its three months average volume of 177,264 shares. In the last year, Jaguar Health's shares have traded in a range of 0.50 - 7.18. The share price has gained 236% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.82 is below its 200-day moving average of $1.79. Shares of Jaguar Health have gained roughly 95.35 percent in the past month and are down 20 percent year-to-date.
Access RDI's Jaguar Health, Inc. Research Report at:
On Tuesday, shares of TG Therapeutics recorded a trading volume of 12,824,182 shares, which was above the three months average volume of 1,079,932 shares. The stock ended the day 44.32% lower at $5.15. The share price has fallen 70.32% from its 52 week high with a 52 week trading range of 5.10 - 17.35. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $11.43 is below its 200-day moving average of $13.15. Shares of TG Therapeutics have fallen roughly 58.80 percent in the past month and are down 37.2 percent year-to-date.
Access RDI's TG Therapeutics, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.